CSIMarket
 
Davita Inc   (NYSE: DVA)
Other Ticker:  
 
    Sector  Healthcare    Industry Healthcare Facilities
   Industry Healthcare Facilities
   Sector  Healthcare
 
Price: $134.9250 $-5.11 -3.646%
Day's High: $140.45 Week Perf: -10.57 %
Day's Low: $ 140.12 30 Day Perf: -9.45 %
Volume (M): 6 52 Wk High: $ 179.60
Volume (M$): $ 890 52 Wk Avg: $150.80
Open: $140.36 52 Wk Low: $128.69



 Market Capitalization (Millions $) 11,774
 Shares Outstanding (Millions) 87
 Employees 70,000
 Revenues (TTM) (Millions $) 12,816
 Net Income (TTM) (Millions $) 1,251
 Cash Flow (TTM) (Millions $) 415
 Capital Exp. (TTM) (Millions $) 555

Davita Inc
DaVita Inc. is a prominent provider of kidney care services, specializing in dialysis treatment for patients with chronic kidney failure, also known as end-stage renal disease (ESRD). The company operates a vast network of outpatient dialysis centers across the United States, where it delivers both standard and specialized dialysis services to its patients.

In addition to its primary focus on dialysis services, DaVita also offers acute inpatient dialysis in approximately 700 hospitals, ensuring that patients receive necessary care during hospital stays. The companys operations are predominantly centered around dialysis and related services, which collectively contribute to about 97% of its total net revenues. The remaining 3% of revenues come from ancillary services and strategic initiatives that further support its core mission of renal care.

DaVita aims to enhance the quality of life for individuals with kidney disease through a comprehensive approach that includes timely care, education, and support for patients and their families. The company strives to improve health outcomes through innovative practices and patient-centric services, establishing itself as a leader in the kidney care sector.


   Company Address: 2000 16th Street Denver, 80202 CO
   Company Phone Number: 631-2100   Stock Exchange / Ticker: NYSE DVA


Customers Net Income grew by DVA's Customers Net Profit Margin grew to

56.05 %

3.56 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ARDT   -2.92%    
CYH   -4.6%    
HCA   -0.88%    
SEM        0.06% 
THC   -1.6%    
UHS   -2.55%    
• View Complete Report
   



Stocks on the Move

DaVita Inc. Continues to Outperform Market Despite FTC Investigation into Noncompete Agreements

Published Tue, Jul 16 2024 5:49 AM UTC

In recent news, DaVita Inc., one of the largest dialysis care providers in the United States, has caught the attention of the Federal Trade Commission (FTC). The FTC has launched an investigation into DaVita Inc. and Fresenius Medical Care AG, the two dominant players in the U.S. dialysis market, over allegations of noncompete agreements that make it difficult for physicians...

Stocks on the Move

Davita Incs Shares Experience Sell-Off Amidst Broader Market Decline

Published Wed, Jul 3 2024 12:31 PM UTC

Davita Inc, a renowned provider of kidney dialysis care, has recently faced a sell-off of its shares with a 2.04% decline on Friday. This downward trend follows three consecutive days of losses for the company s stock. However, it is important to note that Davita s shares have still outperformed the market year to date. This article will delve deeper into the recent sell-off...

Davita Inc

Davita Inc Shines with a 112% Surge in Earnings Per Share: What This Means for Investors



The stock market is constantly influenced by various factors such as earnings reports, revenue growth, and profitability margins. In this article, we will analyze the latest fiscal period of Davita Inc, a prominent player in the Healthcare Facilities sector. We will delve into the interesting facts and figures that highlight the company's performance and its potential impact on the stock market.
Earnings per Share (EPS) Surge:
Davita Inc witnessed a remarkable 112% increase in earnings per share for the most recent fiscal period. This surge amounted to $2.65 per share compared to $1.25 per share in the corresponding period a year prior. Furthermore, in comparison to the previous reporting period, EPS soared by 64.57%, reaching $1.61 per share. Such significant growth in EPS showcases Davita's strong financial standing, which could potentially attract investors.

Davita Inc

Davita Inc. Crushes Expectations with 112.83% Surge in Profits for Q4 2023

Davita Inc. (DVA) has recently reported its financial results for the fourth quarter of 2023, showing an increase in revenue and earnings compared to the previous year. However, a deeper look into the numbers reveals that DVA may not be performing as well as its competitors in the Healthcare Facilities sector.
While revenue increased by 7.846% to $3.15 billion in the most recent fiscal period, DVA's revenue growth lags behind the 21.10% increase reported by its competitors. This underperformance suggests that DVA may be losing market share or facing challenges in growing its business.

Davita Inc

Healthcare Facilities Company Sees Astounding 131.86% Surge in Profits: Impressive Financial Performance Stuns Investors

The stock market has been buzzing with excitement lately, especially when it comes to Davita Inc. This healthcare facilities company has been making waves with its recent financial performance, and investors are taking notice.
One of the most impressive aspects of Davita Inc's recent earnings report is the significant improvement in its income per share. Compared to last year, the company's income per share has skyrocketed by a remarkable 131.86%, reaching $2.62 per share. In addition, profits have grown by an impressive 37.17% from the preceding quarter, coming in at $1.91 per share.







Davita Inc's Segments
Elimination of interrevenues    -0.57 % of total Revenue
Medicare and Medicare Advantage    50.3 % of total Revenue
Medicaid and Managed Medicaid    6.64 % of total Revenue
Other Government Payors    8.67 % of total Revenue
Commercial Payors    31.05 % of total Revenue
Other    0.6 % of total Revenue
U S dialysis    89.04 % of total Revenue
U S dialysis Elimination of interrevenues    -0.49 % of total Revenue
U S dialysis Medicare and Medicare Advantage    50.3 % of total Revenue
U S dialysis Medicaid and Managed Medicaid    6.64 % of total Revenue
U S dialysis Other Government Payors    2.66 % of total Revenue
U S dialysis Commercial Payors    29.26 % of total Revenue
U S dialysis Other    0.19 % of total Revenue
Other Ancillary services    11.53 % of total Revenue
Other Ancillary services Elimination of interrevenues    -0.08 % of total Revenue
Other Ancillary services Medicare and Medicare Advantage    3.19 % of total Revenue
Other Ancillary services Medicaid and Managed Medicaid    -0 % of total Revenue
Other Ancillary services Other Government Payors    6.01 % of total Revenue
Other Ancillary services Commercial Payors    1.8 % of total Revenue
Other Ancillary services Other    0.41 % of total Revenue
U S dialysis External Sources    88.36 % of total Revenue
U S dialysis IntersubEliminations    0.49 % of total Revenue
Other Ancillary services IntersubEliminations    0.08 % of total Revenue
InterElimination    -0.57 % of total Revenue
InterElimination U S dialysis    -0.49 % of total Revenue
InterElimination Other Ancillary services    -0.08 % of total Revenue





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com